• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Kenvue Announces Board Changes with Two New Independent Directors

    7/31/24 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email

    Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors

    Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors

    Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight.

    Appointment of Two New Independent Directors to the Board

    The Board has appointed Kathleen M. Pawlus and Kirk L. Perry as new independent directors, effective August 15, 2024, and December 1, 2024, respectively.

    Ms. Pawlus brings over 40 years of audit, finance, strategy, mergers and acquisitions, quality, information technology and administration experience to the Company, having previously served as a partner at Ernst and Young, LLP ("EY") and Chief Financial Officer and Chief Operating Officer of its Global Assurance group. Upon joining the Board, Ms. Pawlus will serve as a member of the Audit Committee.

    Mr. Perry currently serves as President and Chief Executive Officer of Circana, a global provider of technology, data, and predictive analytics for the consumer, retail and media sectors. He is a seasoned consumer products and brand strategist, with more than 30 years of consumer packaged goods and technology experience at two of the world's largest and most respected companies, Procter & Gamble and Google. Upon joining the Board, Mr. Perry will serve as a member of the Compensation & Human Capital Committee.

    "Entering our second year as an independent public company, our Board succession process will ensure our Board of Directors further strengthens our diverse mix of backgrounds and skills, as well as independent director oversight, as our leadership executes our revenue and margin growth plan and we maintain our commitment to and focus on driving shareholder value," said Larry Merlo, Chair, Kenvue Board of Directors. "We are pleased that Kathleen and Kirk will join our Board. Kathleen and Kirk are highly experienced global leaders with strong track records in finance, consumer brands, and technology. Kathleen brings deep expertise across finance and accounting as well as strategy and operations, and Kirk brings a deep background in consumer packaged goods, brand management, strategy, operations, and technology. We are confident they will be valuable additions to our Board and look forward to gaining from their additional insights."

    "I am thrilled to join the Kenvue Board during this important phase in the Company's evolution," said Ms. Pawlus. "I look forward to leveraging my experience and collaborating with my fellow directors and management to help accelerate the momentum underway as Kenvue continues to advance toward its ambition to become the undisputed leader in consumer health."

    "I am eager to begin working alongside the rest of the Kenvue Board and supporting the management team as the Company executes against its strategic priorities," said Mr. Perry. "It's an honor to join the Board and be a part of bringing Kenvue's iconic brands to market to positively impact people's health and wellness."

    Resignation of Two Current Johnson & Johnson Executives from Board

    Following the sale of Johnson & Johnson's remaining stake in Kenvue in May 2024, Peter M. Fasolo, Ph.D., and Joseph J. Wolk, current Johnson & Johnson executives, advised Kenvue's Board that they will resign from the Board, effective in December 2024, at the time Mr. Perry is expected to join the Board. Following the implementation of this Board succession process, Kenvue expects the Board to be composed of 11 directors, 10 of whom will be independent, as of the Company's 2025 Annual Meeting of Shareholders.

    Mr. Merlo concluded, "On behalf of the entire Board, I would like to thank Peter and Joe for their tremendous contributions as Kenvue separated from Johnson & Johnson. They provided valuable support as the Company formulated and executed on its new strategy, and we appreciate their partnership at such an important time for the business."

    "The Kenvue Leadership Team and I are grateful for Peter's and Joe's commitment to making Kenvue's separation a smooth and successful transition," added Thibaut Mongon, Chief Executive Officer, Kenvue. "We look forward to welcoming Kathleen and Kirk to our Board as we focus on reaching more consumers, reinventing our ways of working to invest more behind our brands, and fostering a culture that rewards performance and impact as we deliver long-term value for our shareholders."

    About Kathleen M. Pawlus

    Kathleen Pawlus previously served as partner of EY, and as Chief Financial Officer and Chief Operating Officer of EY's Global Assurance group, which is one of the largest of EY's four service lines and includes its Audit Practice, Fraud, Investigation and Dispute Services Practice, Climate Change and Sustainability Services Practice and its Financial Accounting Advisory Services Practice. She spent her entire career at EY and brings more than four decades of experience to Kenvue. Prior to her role as Chief Financial Officer and Chief Operating Officer of EY's Global Assurance group, she served as EY's Americas Chief Financial Officer, Global PBFA Function Leader and U.S. Firm Chief Financial Officer responsible for finance, IT operations, treasury, purchasing and facilities. Ms. Pawlus served on EY's U.S. Executive Board from 2006 to 2012. She currently serves as a board member of AMC Entertainment Holdings, Inc. Ms. Pawlus has a B.S. from Indiana University and is a Certified Public Accountant.

    About Kirk L. Perry

    Kirk Perry currently serves as President and Chief Executive Officer and a member of the board of directors of Circana, a global provider of technology, data, and predictive analytics for the consumer, retail and media sectors. He brings a deep understanding of the global consumer marketplace from both the manufacturer and technology-based service provider perspective, with more than 30 years of consumer packaged goods and technology experience. Prior to joining Circana, Mr. Perry served as President, Global Client and Agency Solutions at Google, and was responsible for driving Google's global revenue and growing its relationships with the world's largest advertisers and advertising agencies. Before Google, Mr. Perry spent 23 years with Procter & Gamble, where he held several positions of increasing responsibility in general management and marketing roles, including President of Global Family Care; Vice President, U.S. Operations and North America Marketing, Procter & Gamble's biggest region; and Vice President, North America Baby Care. Mr. Perry currently serves as a board member of The J.M. Smucker Company and Chick-Fil-A, Inc., a privately owned restaurant company. He previously served as a director of e.l.f. Beauty and Hillerich & Bradsby Co. (Louisville Slugger), a privately owned sporting goods manufacturer. He has a B.B.A. from the University of Cincinnati.

    About Kenvue

    Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

    Cautions Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, changes to the Board of Directors. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. Readers are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. A list and descriptions of risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240731940692/en/

    Get the next $KVUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    9/24/2024$24.00Outperform → Sector Perform
    RBC Capital Mkts
    5/28/2024$21.00Neutral
    Citigroup
    4/11/2024$18.00Underperform
    Bernstein
    More analyst ratings

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference

      Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. Thibaut Mongon, Chief Executive Officer, Amit Banati, Chief Financial Officer, and Carlton Lawson, Group President, Europe, Middle East and Africa & Latin America will participate in a fireside chat on Tuesday, June 3, 2025, at 6:00 a.m. Eastern Time / 12:00 p.m. Central European Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be available on the website following the event. About Kenvue Kenvue Inc. is the world's larges

      5/21/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Everyday Care in Action: Thousands of Kenvue Employees Come Together Across 21 Markets to Help Advance Healthier Communities

      Kenvuers contribute 5,000+ hours of volunteer time to local causes along with building 22,000+ hygiene kits for underserved communities Hygiene kits to feature 110,000+ donated products from iconic brands Neutrogena®, Listerine®, OGX®, Johnson's® Baby and more Kenvue Inc. (NYSE:KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced its global community engagement efforts in celebration of Kenvue Cares Week, the company's signature annual volunteer initiative part of its Healthy Lives Mission. Kenvue Cares Week is a testament to the strong Kenvue commitment to advance the well-being of people and our planet, giving back through voluntee

      5/14/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Reports First Quarter 2025 Results

      Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

      5/8/25 6:50:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      11/14/24 1:22:40 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      11/12/24 10:32:12 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

      SC 13G/A - Kenvue Inc. (0001944048) (Subject)

      10/16/24 10:07:52 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Smith Jeffrey C disposed of 1,124,062 shares (SEC Form 4)

      4 - Kenvue Inc. (0001944048) (Issuer)

      5/16/25 9:32:14 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Banati Amit

      3 - Kenvue Inc. (0001944048) (Issuer)

      5/16/25 4:41:26 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Director Smith Jeffrey C

      4 - Kenvue Inc. (0001944048) (Issuer)

      4/2/25 4:36:01 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Kenvue with a new price target

      Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

      4/10/25 12:41:58 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Evercore ISI initiated coverage on Kenvue with a new price target

      Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00

      3/24/25 8:39:49 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously

      1/6/25 8:13:28 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    See more
    • Kenvue Announces Chief Financial Officer Transition

      Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

      5/8/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Three New Appointments to Board of Directors

      Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as

      3/5/25 8:05:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Announces Board Changes with Two New Independent Directors

      Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa

      7/31/24 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    See more
    • Kenvue Reports First Quarter 2025 Results

      Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

      5/8/25 6:50:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue to Announce First Quarter 2025 Results on May 8, 2025

      Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine

      4/24/25 6:45:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • Kenvue Declares Quarterly Cash Dividend

      Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in

      4/16/25 8:19:00 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary

    $KVUE
    SEC Filings

    See more
    • Kenvue Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Kenvue Inc. (0001944048) (Filer)

      5/21/25 6:00:31 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form FWP filed by Kenvue Inc.

      FWP - Kenvue Inc. (0001944048) (Subject)

      5/20/25 4:27:10 PM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 424B5 filed by Kenvue Inc.

      424B5 - Kenvue Inc. (0001944048) (Filer)

      5/20/25 8:45:35 AM ET
      $KVUE
      Specialty Chemicals
      Consumer Discretionary